Omnicell, Inc. reported $1.23B of revenue over the trailing twelve months, +7.9% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.23B (to Q1 2026). Net Income: $20M, trailing twelve months to Q1 2026. Free Cash Flow: $114M, trailing twelve months to Q1 2026. Op Margin: 2.8%, trailing twelve months to Q1 2026.

OMCLOmnicell, Inc.

HealthcareUSD

$33.43

$29.4652 weeks$51.39

OMCL as reported

Omnicell, Inc. reported $1.23B of revenue over the trailing twelve months, +7.9% on the year before. 11 reported series are charted on this page, each one as filed.

$1.23B

Revenue, trailing twelve months · to Q1 2026 · +7.9% against the twelve months before

Net Income: $20M
Net Income · −3.5% year on year · trailing twelve months to Q1 2026
Free Cash Flow: $114M
Free Cash Flow · −8.7% year on year · trailing twelve months to Q1 2026
Op Margin: 2.8%
Op Margin · trailing twelve months to Q1 2026

Every series Ryufin has for OMCL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.23B	+7.9%	Q1 2026
Net Income	$20M	−3.5%	Q1 2026
EPS	$0.44	−4.3%	Q1 2026
Gross Margin	44%	n/a	Q1 2026
Op Margin	2.8%	n/a	Q1 2026
Net Margin	1.7%	n/a	Q1 2026
ROE	1.3%	n/a	Q1 2026
ROA	0.81%	n/a	Q1 2026
ROIC	7.3%	n/a	Q2 2020 · 23 quarters behind
Free Cash Flow	$114M	−8.7%	Q1 2026
P/E	76.0	n/a	today